Ovarian cancer patients rushed on big decisions, cancer charities say

A THIRD of women with advanced ovarian cancer feel they are not given enough time to discuss important life and treatment choices, cancer charities say.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news

Related Links:

Conditions:   Epithelial Ovarian;   Fallopian Tube;   Primary Peritoneal Cancer Interventions:   Drug: Paclitaxel/Bev (control);   Drug: Paclitaxel/Bev + ZA (experimental) Sponsors:   M.D. Anderson Cancer Center;   Gateway for Cancer Research;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Mol Med Rep. 2021 Nov;24(5):812. doi: 10.3892/mmr.2021.12452. Epub 2021 Sep 22.ABSTRACTMicroRNA (miR)‑125a‑5p represses tafazzin phospholipid‑lysophospholipid transacylases (TAFAZZIN) expression and inhibits the epithelial‑mesenchymal transition (EMT) of ovarian cancer cells. EMT was found to have a crucial role in the acquisition of chemoresistance. Thus, the present study aimed to determine whether miR‑125a‑5p reverses EMT and restores drug sensitivity by negatively regulating TAFAZZIN in breast cancer. The expression of miR‑125a‑5p/TAFAZZIN and its association with chemotherapy response were determined i...
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
Cancers, Vol. 13, Pages 4739: Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients Cancers doi: 10.3390/cancers13194739 Authors: Jalid Sehouli Alexander Mustea Guelten Oskay-Özcelik Maren Keller Rolf Richter Oliver Tomé Hannah Woopen Ann-Katrin Sommer-Joos Jacek P. Grabowski Robert Armbrust Wimberger In the single-arm non-interventional OTILIA study, patients with newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) stage IIIB&n...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Source Type: research
Source: Clinical Epidemiology - Category: Epidemiology Tags: Clinical Epidemiology Source Type: research
AbstractNoscapine has been mentioned as one of the effective drugs with potential therapeutic applications. With few side effects and amazing capabilities, noscapine can be considered different from other opioids-like structure compounds. Since 1930, extensive studies have been conducted in the field of pharmacological treatments from against malaria to control cough and cancer treatment. Furthermore, recent studies have shown that noscapine and some analogues, like 9-bromonoscapine, amino noscapine, and 9-nitronoscapine, can be used to treat polycystic ovaries syndrome, stroke, and other diseases. Given the numerous resul...
Source: BioFactors - Category: Biochemistry Authors: Tags: Review Article Source Type: research
We describe the first case of a girl with NBS with PGD, who developed metachronous bilateral ovarian germ cell tumors (dysgerminoma and gonadoblastoma). Pathogenesis of PGD, neoplastic transformation and therapeutic approach in females with NBS are discussed.PMID:34544220 | DOI:10.4274/jcrpe.galenos.2021.2021.0151
Source: JCRPE Journal of Clinical Research in Pediatric Endocrinology - Category: Endocrinology Authors: Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
In this study, we retrospectively analyzed prevalence and geographic distribution of pathogenic germline BRCA1/2 variants in families from Apulia in southern Italy and evaluated the genotype–phenotype correlations. Data were collected from Oncogenetic Services present in Apulian hospitals and a shared database was built containing Apulian native probands (n = 2026) that had undergone genetic testing from 2004 to 2019. PVs were detected in 499 of 2026 (24.6%) probands and 68.5% of them (342 of 499) were in the BRCA1 gene. We found 65 different PVs in BRCA1 and 46 in BRCA2. There were 10 most recurrent PVs and their ge...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CDK12 biallelic inactivation is associated with a distinct genomic signature of focal tandem duplications (FTDs). Gene fusions resulting from FTDs increase neoantigen load, raising interest in CDK12 as a biomarker of response to immune checkpoint inhibitors (ICIs). Despite evidence of FTDs in multiple CDK12-altered cancer types, notably for prostate and ovarian, report of fusion-associated neoantigen load is limited to prostate cancer. Molecular profiles were retrospectively reviewed for CDK12-biallelic (CDK12-biLOF) and -monoallelic loss-of-function (CDK12-monoLOF) in a primary cohort of>9,000 tumors, representing 39 c...
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Regular Article Source Type: research
More News: Cancer | Cancer & Oncology | Health | Ovarian Cancer | Ovaries | Women